The Imugene Limited (ASX: IMU) share price took off today despite the company’s silence.
However, today’s gains might have been a belated reaction to the news the company announced to the ASX yesterday.
As of Thursday’s close, the Imugene share price is 20 cents. That’s 17.65% higher than it was at the end of Wednesday’s session. It reached an intraday high of 21.5 cents today, representing a 26.47% gain.
For context, the S&P/ASX 200 Index (ASX: XJO) finished the day 1.6% lower.
Let’s take a closer look at the latest news from the clinical-stage immuno-oncology company.
Did this drive the Imugene share price today?
The Imugene share price leapt higher today as the healthcare sector outperformed.
In fact, the stock’s sector, represented by the S&P/ASX 200 Health Care Index (ASX: XHJ), was the only one in the green today. It closed 0.1% higher and was, perhaps unsurprisingly, led by Imugene.
The stock’s movement comes one day after the company announced the first patient has been dosed in its phase 1 clinical trial of its cancer-killing oncolytic virus CF33-hNIS, Vaxinia.
The trial is the first time the virus has come up against tumours in humans.
It has previously been shown to shrink colon, lung, breast, ovarian, and pancreatic cancer tumours in preclinical laboratory and animal models.
The study is being run in partnership with City of Hope. That’s the cancer treatment and research organisation that developed the virus. The study aims to recruit 100 patients across Australia and the United States.
The Imugene share price gained 3% yesterday. Though, the stock has notably underperformed throughout 2022 so far.
It is 53% lower than it was at the start of 2022. It has also fallen 50% since this time last year.
The post Imugene share price surges 18% to lead the ASX 200 on Thursday appeared first on The Motley Fool Australia.
Should you invest $1,000 in Imugene right now?
Before you consider Imugene, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Imugene wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of January 13th 2022
More reading
- 2 ASX All Ordinaries shares having a cracking day, despite the carnage
- ASX 200 midday update: Aristocrat’s earnings beat, Webjet flops, retailers smashed
- Here’s why the Imugene share price just got a boost
- Why Imugene, Integrated Research, Monash IVF, and Step One shares are sinking
- ASX 200 midday update: Brambles rockets, Goodman upgrades guidance
Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/hx9Miks
Leave a Reply